4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
14.70
-0.24 (-1.61%)
At close: Sep 3, 2026, 4:00 PM EDT
14.52
-0.18 (-1.22%)
After-hours: Sep 3, 2026, 6:02 PM EDT

4D Molecular Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, 4D Molecular Therapeutics stock has a consensus rating of "Buy" and an average price target of $29.1. The average 1-year stock price forecast is 97.96% higher than the current stock price, while the lowest is $18 (+22.45%) and the highest is $37 (+151.70%).

Price Target: $29.1 (+97.96%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$18$29.1$30.5$37
Change+22.45%+97.96%+107.48%+151.70%

Analyst Ratings

The average analyst rating for 4D Molecular Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy777788
Buy222222
Hold222222
Sell000000
Strong Sell000000
Total111111111212

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Morgan Stanley
Morgan Stanley
Hold
Reiterates
n/a
HoldReiteratesn/an/aAug 17, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
n/a
BuyMaintainsn/an/aAug 14, 2026
RBC Capital
RBC Capital
Buy
Reiterates
$35
BuyReiterates$35+138.10%Aug 14, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Maintains
n/a
HoldMaintainsn/an/aAug 14, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$36
BuyReiterates$36+144.90%Aug 14, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
12.77M
from 85.21M
Decreased by -85.02%
Revenue Next Year
21.20M
from 12.77M
Increased by 66.07%
EPS This Year
-4.14
from -2.42
EPS Next Year
-4.09
from -4.14
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
18.04M3.13M20.72M37.00K85.21M12.77M
Revenue Growth
32.52%-82.65%562.29%-99.82%230,194.59%-85.02%
Operating Income
-71.33M-110.03M-112.87M-187.84M-156.35M-310.20M
Net Income
-71.32M-107.49M-100.84M-160.87M-140.11M-292.98M
EPS
-----2.42-4.14
Free Cash Flow
-41.00M-59.70M-46.48M-82.29M-54.15M-292.61M
No. Analysts
-----9
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High22.5M
Avg12.8M
Low6.8M

Revenue Growth

Revenue Growth202620272028
High
-73.6%
Avg
-85.0%
Low
-92.0%

EPS Forecast

EPS202620272028
High-4.00
Avg-4.14
Low-4.22

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-